What Jubilant HollisterStier does

Jubilant HollisterStier (JHS) is a US-headquartered contract development and manufacturing organization (CDMO) specializing in sterile fill-finish and lyophilization services for injectable pharmaceuticals. The company operates two production sites — Spokane, Washington (headquarters and primary site) and Kirkland/Montreal, Quebec — with a combined footprint of four sterile filling lines (three operational, one launching mid-2026) and a manufacturing capacity of approximately 60 million vials annually once Line 4 is complete. JHS serves large pharmaceutical companies, emerging biotechnology firms, and government health agencies (US DoD, CDC, BARDA, SNS, and Canadian Strategic Innovation Fund), generating revenue primarily through contract manufacturing fees, technology transfer, and project-based pricing; specific contract values are not publicly disclosed.

The technical platform centers on EU Annex 1-compliant isolator technology, automated lyophilization with -55°C to -60°C cold shelf loading and automated loading/unloading systems (ALUS), high-speed bulk sterile filling (up to 300 vials/minute, 2,000L batch capacity), and automated visual inspection (AIM Körber Seidenader MS-60 at 600 vials/minute) combined with AI-enabled predictive maintenance for critical utilities. Supporting services include regulatory affairs across eight-plus jurisdictions, analytical and quality control testing, validated cold storage (2-8°C to -80°C), Foreign Trade Zone subzone access at Spokane, and tech transfer/clinical-to-commercial NPI services. The 92% customer repeat-project rate and a 15+ year partnership with a Top 20 global pharma firm indicate strong client retention.

JHS is a wholly owned subsidiary of Jubilant Pharmova Limited (Indian publicly listed parent, NSE/BSE: JUBILANTPHARMOVA), incorporated in 1999 when the CMO business was carved out from Hollister-Stier Laboratories (founded 1921). The company underwent a major capital expansion cycle beginning in 2021 totaling approximately $300M+ at Spokane and $114M USD at Montreal, financed through parent equity, a $149.6M US Government cooperative agreement (BARDA), and a CAD 25M Quebec government loan. Regulatory posture is currently mixed: the 2024 FDA inspection at Spokane yielded zero observations, but the October-November 2025 FDA inspection at the Kirkland facility triggered a Warning Letter for CGMP and aseptic processing violations, placing that site under extended shutdown pending remediation, and a June 2026 Spokane inspection yielded eight observations (none related to sterility assurance).

Name

Jubilant HollisterStier

Legal name

Jubilant HollisterStier LLC

Website

https://jublhs.com

Company type

Private

Founded year

1921

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Jubilant HollisterStier is a US-based CDMO providing sterile fill-finish and lyophilization contract manufacturing for injectable pharmaceuticals, serving pharmaceutical, biotech, and government health agency clients from facilities in Spokane, WA and Montreal, Canada.

Ownership category

akta.pro rank

Product category

Sterile Injectable Contract Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Sterile fill-finish services
• Lyophilization manufacturing
• Pharmaceutical contract manufacturing
• Aseptic injectable production
• Biologics manufacturing services

Headquarters

HQ city

Spokane

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Jubilant HollisterStier generates revenue primarily through contract manufacturing fees for sterile fill-finish and lyophilization services. As a CMO/CDMO, they provide manufacturing services to pharmaceutical companies for both clinical trial and commercial-scale production. Revenue is generated through project fees, technology transfer fees, and manufacturing charges based on batch production and per-unit pricing.
2. Analytical and Quality Control Services: The company provides comprehensive analytical laboratory testing services including chemical, biochemical, protein, microbiological, and physical property testing. These services support product release, stability studies, validation, and regulatory submissions as part of their integrated service offering.
3. Support Services: Additional revenue streams include regulatory support, new product introductions (NPI), supply chain and cold storage services, clinical trial manufacturing, secondary packaging, and Foreign Trade Zone (FTZ) benefits that provide cost advantages to customers.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Jubilant HollisterStier is a contract manufacturing organization (CMO) providing sterile fill-finish and lyophilization services for injectable pharmaceuticals. The company operates EU Annex 1 compliant isolator-based filling lines, advanced lyophilization with automated loading systems, automated visual inspection, and validated cold storage to support clinical through commercial-scale production for pharmaceutical and biotech clients.

Product overview

Jubilant HollisterStier is a contract manufacturing organization (CMO) providing comprehensive sterile fill-finish and lyophilization services for sterile injectables. The company operates a platform-based service model centered around three core products: Sterile Fill-Finish (liquid injectable manufacturing with isolator technology), Lyophilization (freeze-drying services for biologics and temperature-sensitive products), and Inspection and Packaging (automated visual inspection and integrated packaging). These core services are supported by a comprehensive suite of eleven support services including Regulatory Support, Analytical and Quality Control Services, Government Partnerships, New Product Introductions (NPI), Supply Chain and Cold Storage, Clinical Trial Manufacturing, Foreign Trade Zone (FTZ), and Secondary Packaging. The company serves both large pharmaceutical companies and emerging biotech organizations, offering flexible capacity from clinical to commercial scale.

Differentiator

Problem solved

Functional benefit

Products and services

• Sterile Fill-Finish Sterile fill-finish liquid product manufacturing services for both clinical and commercial-scale projects, featuring isolator technology compliant with EU Annex 1 and vial sizes from 2mL to 100mL with batch capacity up to 2,000L. Designed for pharmaceutical and biotech companies requiring aseptic injectable production.
• Lyophilization Freeze-drying (lyophilization) services for sterile liquid injectables including biologics, with full line integration, automated loading/unloading systems (ALUS), SIP/CIP capability, and 240-400ft² shelf space per unit supporting batch sizes up to 180,000 2ml vials.
• Inspection and Packaging End-to-end automated visual inspection (AVI) using AIM Körber Seidenader MS-60 (600 vials/minute), combined with semi-automated visual inspection (SAVI), manual inspection booths, and integrated packaging services including labeling, serialization, and custom packaging solutions.
• Regulatory Support Comprehensive regulatory affairs guidance for submissions to US FDA, Health Canada, PMDA Japan, EMA EU, MFDS South Korea, ANVISA Brazil, TGA Australia, MOH Russia, and MOH Türkiye. Supports clients through global regulatory pathways.
• Analytical and Quality Control Services Full-range testing services including chemical, biochemical, protein, microbiological, and physical property testing for quality assurance, stability studies, validation, and regulatory submissions.
• Clinical Trial Manufacturing Fill-finish and lyophilization services for clinical trials with flexible capacity, supporting batch size changes during clinical to commercial production transitions. Designed for biotech and pharma companies advancing drug candidates.
• New Product Introductions (NPI) Tech transfer and new product introduction processes ensuring smooth transitions from clinical to commercial production with process performance qualification batches and stability studies.
• Supply Chain and Cold Storage

Quantifiable outcome

• 92% of customers give JHS a second project, demonstrating high customer satisfaction and retention
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered minor, major and core.

• Spokane Community CollegeminorStrategic or Co-development Partner · 26 June 2025JHS partnered with Spokane Community College to launch the Essentials in Biomanufacturing Certification program, creating a workforce development pipeline for the biomanufacturing industry. Ten students graduated from the inaugural cohort in June 2025.
• OcugenmajorStrategic or Co-development Partner · 15 June 2021JHS partnered with Ocugen for US production of COVAXIN COVID-19 vaccine candidate, supporting the company's efforts to bring the vaccine to the US market.
• Eli LillymajorStrategic or Co-development Partner · 9 March 2021During the height of the COVID-19 pandemic, JHS entered into a contract with Eli Lilly to manufacture bamlanivimab, a therapeutic COVID-19 treatment. This partnership demonstrates the company's ability to respond quickly to emergency manufacturing needs.
• US Government (DoD, CDC, BARDA, SNS)coreStrategic or Co-development PartnerJHS serves as a preferred large-scale fill/finish partner for the US government, partnering with DoD, CDC, BARDA, and the Strategic National Stockpile (SNS) to address critical health threats including COVID-19, H7N9 Influenza, botulinum toxin, and plague. A $149.6M cooperative agreement was signed to expand critical vaccine manufacturing capacity.

Scale indicators14 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO offering sterile fill-finish alongside its mAb manufacturing footprint; comparable to JHS in targeting biologics sponsors with high-speed, regulatory-compliant injectable capacity.
• WuXi STA: WuXi STA is the CDMO arm of WuXi AppTec, offering sterile injectable fill-finish and biologics manufacturing; directly comparable to JHS in service scope, though the BIOSECURE Act creates divergent geographic access dynamics.
• AGC Biologics: AGC Biologics is a mid-sized CDMO providing mammalian biologics manufacturing and aseptic fill-finish, comparable to JHS in targeting biotech and pharma customers with clinical and commercial-scale injectable needs.
• Catalent: Catalent (now owned by Novo Holdings) is one of the largest global CDMOs with a major sterile fill-finish and lyophilization franchise serving pharma and biotech — directly comparable to JHS in core services, customer profile, and regulatory-driven differentiation.
• Baxter BioPharma Solutions: Baxter's BioPharma Solutions business is a contract manufacturer of sterile injectables and lyophilized products, competing head-to-head with JHS for pharma and biotech fill-finish contracts in the same clinical-to-commercial service envelope.
• Recipharm: Recipharm (EQT-owned) is a European CDMO with sterile injectable fill-finish capabilities alongside oral solids and other dosage forms; comparable to JHS in pharma contract manufacturing service model and regulatory focus.
• Vetter Pharma: Vetter is a privately-held German CDMO specializing in sterile injectable fill-finish and lyophilization for biologics — overlapping JHS in vial/syringe aseptic processing, complex formulation handling, and regulatory-grade quality systems.

Broad incumbents

• Patheon (Thermo Fisher): Patheon, now part of Thermo Fisher, is a global CDMO with sterile injectable manufacturing services — historically one of the most direct comparables to JHS in pharma contract manufacturing scope and customer profile.
• Lonza: Lonza is a global, diversified CDMO with substantial sterile injectable and biologics fill-finish capacity; broader and larger than JHS but directly competing in mammalian biologics manufacturing and aseptic vial filling.
• Thermo Fisher Scientific (Pharma Services): Thermo Fisher's Pharma Services segment offers sterile fill-finish and contract manufacturing as part of a much larger life-sciences services portfolio; competes with JHS on injectable manufacturing while bundling broader analytical and clinical services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/JubilantHStier
• Facebookfacebook.com/JubilantHollisterStier
• LinkedInlinkedin.com/company/jubilant-hollisterstier-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jubilant HollisterStier